VXRT — Vaxart, Inc.

VXRT Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: Vaxart reported full-year 2025 revenue of $237.3 million, a significant increase from $28.7 million in 2024, primarily driven by government contracts and the Dynavax collaboration.
• Cash Position: As of the end of Q4 2025, the company had cash, cash equivalents, and investments totaling $63.8 million, with an expected cash runway extending into 2027.

2. Strategic Updates and Business Highlights:

• Partnership with Dynavax: Vaxart established a partnership with Dynavax for its oral COVID-19 vaccine, receiving a $25 million upfront payment and a $5 million equity investment. The agreement has a total potential value of up to $700 million, contingent on development milestones.
• Clinical Trials: The company is conducting a Phase 2b trial for its oral COVID-19 vaccine, with preliminary safety data expected in early Q2 2026. The trial will compare the oral vaccine's efficacy against an mRNA vaccine.
• Norovirus Vaccine Progress: Vaxart published data from a Phase 1 study of its oral norovirus vaccine in lactating mothers, showing promising safety and immunogenicity results. Plans for a Phase 2 trial of the second-generation norovirus vaccine are in progress, pending partnership or funding.

3. Forward Guidance and Outlook:

• Vaxart anticipates reporting top-line data from the 400-participant sentinel cohort of the COVID-19 trial in early Q2 2026, with efficacy data from the larger 5,000-participant cohort expected later in 2026.
• The company remains focused on securing additional partnerships and funding to support its pipeline, particularly for the norovirus program.

4. Bad News, Challenges, or Points of Concern:

• Delay in Data Reporting: There is a slight delay in reporting the 400-person cohort data, now expected in early Q2 instead of late Q1, which may raise concerns about timelines and execution.
• Regulatory Dependencies: The company’s timelines are heavily influenced by BARDA, which could introduce uncertainties in data release and trial progression.
• Market Competition: The competitive landscape in vaccine development, particularly with established players like Sanofi, poses a risk to Vaxart's market position and future collaborations.

5. Notable Q&A Insights:

• Data Timing Clarification: Management confirmed that the 400-person cohort is primarily a safety cohort, and while initial efficacy insights will be provided, comprehensive immunogenicity data will follow later.
• Regulatory Engagement: Vaxart has been in ongoing discussions with the FDA regarding endpoints for the norovirus vaccine, indicating a proactive approach to regulatory compliance and strategy.
• Future Collaboration Potential: The company is actively seeking partnerships to advance its norovirus program, highlighting the importance of external funding and collaboration in their growth strategy.

Overall, Vaxart is positioned with a strong financial foundation and promising clinical developments, but it faces challenges related to data timelines and competitive pressures in the vaccine market.